Zealand Pharma — Marts 2022
-
(...) continue to believe that Zealand is undervalued based on its late-stage pipeline, but we acknowledge that the stock will likely remain depressed and range-bound until its high-impact pipeline data materialises – in particular the ph III glepaglutide data in SBS during Q3 2022
-
@Cubinvest2021 - tak!
-
Så er vi tilbage i samme kurs som for 4 år siden... SUK
-
De professionelle shortere kan sagtens presse kursen ned for at aktivere stop loss og købe i bunden, men det her ligner mere øgede shortpositioner
-
"Needham & Company Reiterates Zealand Pharma (ZEAL) at Buy, Short Bowel Syndrome Program Remains Main Value Driver"
"Needham & Company analyst Joseph Stringer reiterated a Buy rating and $42.00 price target on Zealand Pharma A/S (NASDAQ: ZEAL) .."Svarer til kurs DKK 284,-
-
Zealand Pharma/Nordea: Sænker kursmål med en tyver https://proinvestor.com/investornyt/794047/zealand-pharma-nordea-saenker-kursmal-med-en-tyver
-
Zealand Pharma/Danske: Sænker kursmål til 250 kr. fra 285 kr. https://proinvestor.com/investornyt/794062/zealand-pharma-danske-saenker-kursmal-til-250-kr-fra-285-kr
-
Har også suppleret - når man ser de off mægleres target på ca 200 og kun små ned justeringer virker faldet stort?
-
@johnlau - tak for stregerne - gav mig deet sidste puf til at hu
gge til rundt 79 - sofar so good -
Så nu kollapsede den og gik i handelsstop ved 77,35
-
Det er et godt spørgsmål. Med en volumen i dag på ca. 1.083.000 aktier kontra en gennemsnitlig volumen på ca. 167.000...
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind